The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
Researchers have created a tool that uses machine learning to assess a non-Hodgkin lymphoma (NHL) patient’s likely response to chimeric antigen receptor (CAR)
In this video interview, Jodi Lipof, MD, explains why Myeloma Awareness Month matters more than ever.
The addition of pevonedistat to azacitidine plus venetoclax failed to significantly improve response rates.
Lisocabtagene maraleucel (liso-cel) was found to offer a favorable benefit–risk profile relative to mosunetuzumab as a third-line or later treatment for relapsed or refractory
The European Commission (EC) has granted approval to lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for the treatment of
The European Commission (EC) has approved the marketing authorization for imetelstat (RYTELO), a first-in-class telomerase inhibitor, as a monotherapy for the treatment of
A study documenting peripheral T-cell lymphoma epidemiology across Latin America found a high prevalence of adult T-cell leukemia or lymphoma and extranodal natural
Ketogenic diet-derived BHB can be provided as a dietary intervention to augment CAR-T function in multiple cancer models.
The combination of olutasidenib plus azacitidine produced “durable” responses in patients with relapsed or refractory mIDH1 acute myeloid leukemia (AML), according to a
In every phase of my career while I’ve been training, I have been lucky to be mentored by the major movers and shakers
